Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Ann Mullally is a physician-scientist at Brigham and Women’s Hospital (BWH) / Dana-Farber Cancer Institute (DFCI). Her laboratory studies the genetics, biology and therapy of myeloproliferative neoplasms (MPN) using MPN patient samples, mouse models and multiple different laboratory approaches. Dr. Mullally’s MPN research interests include myelofibrosis, the biology of mutant calreticulin (CALR) in MPN, JAK2V617F MPN stem cells, improving the efficacy of JAK2 inhibitors and familial forms of MPN. The overarching goal of the research in her laboratory is to advance the understanding of the biology of MPN and to translate this into improved treatment options for patients dealing with these diseases.
Dana-Farber Cancer Institute450 Brookline AvenueBoston, MA 02215Get Directions